[{"orgOrder":0,"company":"Dualyx","sponsor":"Fountain Healthcare Partners","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"BELGIUM","productType":"Other Large Molecule","year":"2023","type":"Series A Financing","leadProduct":"DT-001","moa":"TNF2 receptor","graph1":"Immunology","graph2":"IND Enabling","graph3":"Dualyx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dualyx \/ Fountain Healthcare Partners","highestDevelopmentStatusID":"5","companyTruncated":"Dualyx \/ Fountain Healthcare Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Dualyx

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : The use of proceeds will enable the development of the Company’s lead autoimmune program DT-001, targeting the highly attractive TNF receptor 2 (TNFR2) and widely regarded as a master control switch in immune modulation, as well as its pipeline of Treg...

                          Product Name : DT-001

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          May 15, 2023

                          Lead Product(s) : DT-001

                          Therapeutic Area : Immunology

                          Highest Development Status : IND Enabling

                          Sponsor : Fountain Healthcare Partners

                          Deal Size : $44.0 million

                          Deal Type : Series A Financing

                          blank